Abstract
BackgroundOncology therapy is becoming increasingly more expensive and challenging the affordability and sustainability of drug programmes around the world. When new drugs are evaluated, health technology assessment organisations rely on clinical trials to inform funding decisions. However, clinical trials are not able to assess overall survival and generalises evidence in a real-world setting. As a result, policy makers have little information on whether drug funding decisions based on clinical trials ultimately yield the outcomes and value for money that might be expected.ObjectiveThe Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration, consisting of researchers, recommendation-makers, decision makers, payers, patients and caregivers, are developing and testing a framework for Canadian provinces to generate and use real-world evidence (RWE) for cancer drug funding in a consistent and integrated manner.StrategyThe CanREValue collaboration has established five formal working groups (WGs) to focus on specific processes in the generation and use of RWE for cancer drug funding decisions in Canada. The different RWE WGs are: (1) Planning and Drug Selection; (2) Methods; (3) Data; (4) Reassessment and Uptake; (5) Engagement. These WGs are acting collaboratively to develop a framework for RWE evaluation, validate the framework through the multiprovince RWE projects and help to integrate the final RWE framework into the Canadian healthcare system.OutcomesThe framework will enable the reassessment of cancer drugs, refinement of funding recommendations and use of novel funding mechanisms by decision-makers/payers across Canada to ensure the healthcare system is providing clinical benefits and value for money.
Funder
Canadian Institutes of Health Research
Reference32 articles.
1. Anas R , Gavura S , McLeod R , et al . Ontario’s approach to tackling drug funding sustainability. J Clin Oncol 2016;34:38.doi:10.1200/jco.2016.34.7_suppl.38
2. Canadian Institute for Health Information . National health expenditure trends, 1975 to 2017. Ottawa, ON, 2017.
3. Cancer Quality Council of Ontario . Sustainable cancer care: strengthening the system for future generation. Toronto, ON, 2016.
4. Murphy G . Use of real-world evidence in single-drug assessments. Ottawa, ON: CADTH, 2018.
5. Canadian Partnership Against Cancer and pCODR . How cancer drug funding decisions are made, 2013.
Cited by
34 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献